Navigation Links
Genetics Squared Changes Name To Everist Genomics
Date:1/10/2011

ANN ARBOR, Mich., Jan. 10, 2011 /PRNewswire/ -- Genetics Squared, a prognostics company focused on developing gene-based molecular assays for the prediction of cancer recurrence, today announced that it will change its corporate name to Everist Genomics and has appointed Prasad Sunkara, Ph.D. as its new President and Chief Executive Officer, effective immediately.

(Logo: http://photos.prnewswire.com/prnh/20110110/NY26865LOGO)

In connection with these changes, the company is poised to launch its first prognostic gene-based laboratory test—OncoDefender™-CRC—intended to help guide treatment decisions following surgery for Stage I/II colon cancer and Stage I rectal cancer.  Of the estimated 68,000 patients that will be diagnosed with early-stage colorectal cancer this year in the U.S. (approximately 22,000 Stage I, and 46,000 Stage II), 90% of those with Stage I and 70% of those with Stage II likely will be cured by surgery alone.  The remaining 10% of those with Stage I and 30% with Stage II will ultimately recur and die of advanced colorectal cancer, consequent to undetected tumor remaining following definitive surgery.(1)

Dr. Prasad Sunkara, President and CEO of the Company, commented, "We believe that our new corporate name more accurately reflects our company's broader mission to develop and commercialize a range of prognostic products that will give physicians more patient-specific clinical information so that they can make informed decisions and improve clinical outcomes.  I am excited to lead Everist during this next period of growth and development as we prepare to launch and commercialize the OncoDefender laboratory assay."    

Dr. Sunkara succeeds Bill Worzel, who co-founded Everist in 2002 and led the company through cutting-edge research in genetic programming and molecular prognostics to prepare the company for commercialization. Worzel will remain with company in the new role of Chief Technology Officer.

"With a new name and expanded leadership, Everist Genomics begins a new era in our evolution from a research-based start-up to a commercial enterprise," said Mr. Worzel.  "As we prepare to launch the first of several innovative products that promise to change the way we predict the evolution and recurrence of disease, Prasad's track record of managing biotechnology and medical device companies will prove invaluable for Everist.  I look forward to continuing to contribute to the Company's success as Chief Technology Officer as we continue to innovate our product portfolio based on even more advanced and effective algorithms."

"We thank Bill for his leadership, vision and expertise in genetics programming which have created a strong foundation for Everist to lead the emerging discipline of disease prognostics," Dr. Sunkara said of Worzel's contributions.

Dr. Sunkara has held executive roles at a number of biotechnology, pharmaceutical and medical device companies, including Cytovia, Inc., Molecular Therapeutics, Inc. and Cascade Pharmaceuticals, Inc.  Most recently, he served as chairman of medical diagnostics company Angiologix, in which Everist previously acquired a controlling interest.  Dr. Sunkara has more than 30 years of corporate, financing, research and development and management experience in cancer, cardiovascular and CNS disease indications.  Dr. Sunkara has also co-founded and served as Chief Executive Officer of four previous companies, the most recent of which was Ann Arbor Michigan headquartered Molecular Imaging Research Inc. which he successfully sold to Charles River Laboratories in September of 2008.  He received a Ph.D. in microbial biochemistry from Indian Institute of Science and completed a post-doctoral fellowship in cell and tumor biology at M.D. Anderson Cancer Center, Houston, Texas.

Worzel, who has served as Everist's CEO since 2006, was instrumental in forming partnerships with several academic institutions, along with the Armed Forces Institute of Pathology, to conduct clinical studies validating the company's patented prognostic technology. Under his guidance, the company also obtained a 21st Century Jobs Fund Award from the State of Michigan and raised more than twice the original amount funded by the state. He formerly served as the Chief Technology Officer at Widevine Technologies, an Internet company based in Seattle, WA.

Everist's acquisition of a controlling interest in Angiologix provides the company a promising candidate to add to its prognostics pipeline. The new product, AngioDefender™, is a sensor device that measures data related to endothelial function, a key risk indicator for atherosclerosis and cardiovascular disease, to screen patients for preventative therapy. The company plans to launch AngioDefender in Europe and India during Q2 of 2011 and in the North America during Q4 of 2011.

The Everist Company was a key supporter and early investor in the company.

(1) El-Deiry WS. Colon cancer, adenocarcinoma, 2006, http://emedicine.medscape.com/article/277496-overview



About Everist Genomics

Everist Genomics is a prognostics company focused on developing gene-based molecular assays for the prediction of cancer recurrence and proprietary point-of-care equipment for the evaluation and management of cardiovascular disease.  Using its patented, evolutionary drug development™ technology and methods, Everist Genomics is able to produce molecular signatures which are aimed at fostering personalized medicine.  These technologies generate information that healthcare providers and patients can use in making individualized treatment decisions.  The privately owned company was founded in 2002 and is located in Ann Arbor, Michigan.  For more information, please visit www.everistgenomics.com.


'/>"/>
SOURCE Everist Genomics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambry Genetics Launches Illumina HiSeq 2000 Next Generation Sequencing Services
2. London Genetics and Astrimmune to Collaborate on Cancer Vaccine
3. Interleukin Genetics Reports Third Quarter 2010 Financial Results
4. Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
5. New England Biolabs Launches a Suite of Innovative Tools to Advance Epigenetics Research, Including PCR-Based Assay to Identify and Quantitate 5-hmC in Epigenome
6. Diaceutics and London Genetics Partner to Accelerate Biomarker Development in the Global Biopharmaceutical Industry
7. Ambry Genetics Becomes First Certified Service Provider in US for NimbleGen SeqCap EZ Exome
8. Reportlinker Adds Epigenetics: Current and future applications that are driving novel drug discovery
9. Ambry Genetics Announces the Addition of Illumina HiSeq 2000 and First 510(K) Approved BeadXpress® to Its Sequencing and Genotyping Capabilities
10. Interleukin Genetics Moves Trading of Stock to OTCQB Marketplace
11. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
Breaking Medicine News(10 mins):